|
Title
|
|
|
|
Motion management during SBRT for oligometastatic cancer: Results of a prospective phase II trial
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Purpose: To optimize the local control of stereotactic body radiotherapy (SBRT) using the Vero-SBRT system and respiratory motion management in patients with oligometastatic cancer. Materials and methods: Patients with five or less metastases were eligible. In metastases with significant motion, a fiducial was implanted for Vero dynamic tracking. For other metastases an internal target volume (ITV) was defined to encompass the respiratory tumor trajectory. A dose of 50 Gy in 10 fractions was prescribed on the 80% isodose line. Results: We treated 87 metastases in 44 patients, with colorectal cancer as the most common primary origin (65.9%). Metastatic sites were mainly lung (n = 62) and liver (n = 17). Twenty-seven metastases were treated with dynamic tracking, the remaining 60 using the ITV-concept. Three patients (7%) experienced grade >= 3 toxicity. After a median follow-up of 12 months, the overall one-year local control (LC) amounted to 89% (95% CI 77-95%), with corresponding values of 90% and 88% for the metastases irradiated with the ITV-approach and dynamic tracking, respectively. Median progression-free survival reached 6.5 months, one-year overall survival 95%. Conclusions: SBRT with proper respiratory motion management resulted in a high LC and an acceptable toxicity profile in oligometastatic cancer patients. (C) 2016 Elsevier Ireland Ltd. All rights reserved. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Radiotherapy and oncology. - Amsterdam
| |
|
Publication
|
|
|
|
Amsterdam
:
2016
| |
|
ISSN
|
|
|
|
0167-8140
| |
|
DOI
|
|
|
|
10.1016/J.RADONC.2016.04.020
| |
|
Volume/pages
|
|
|
|
119
:3
(2016)
, p. 519-524
| |
|
ISI
|
|
|
|
000380075400023
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|